Top

Outcome of patients with Intermediate risk Acute Myelogenous Leukemia in first remission and no detectable residual disease (MRD negative) transplanted with a haploidentical donor versus autografted

Study type:

Retrospective Studies

Study number:

8421116

Type of Stem Cell Treatment:

Diseases:

Acute Myeloid Leukaemia (AML)

Short title:

Primary objective:

The primary endpoint will be the Overall Survival (OS)

Key inclusion criteria:

 Adult patients >18 years old.
 Transplant years between 2010-2019.
 First HSCT:auto-graft or Haploidentical transplantation.
 Acute Myelogenous Leukemia in 1st CR.
 Sources of stem cells PB, BM or PM+BM.
 Intermediate cytogenetics by MRC classification.
 MRD tested and negative (all means, immunophenotyping or molecular biology)

Country:

Principal investigator:

Norbert-Claude GORIN